Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ONCOGENEX PHARMACEUTICALS Inc OGXI

Healthcare Biotechnology
"OncoGenex Pharmaceuticals Inc is a biopharmaceutical company focused on the development of cancer treatment resistance. It has developed Apatorsen to block the production of heat shock protein 27, or Hsp27, that promotes treatment resistance in cancer."

Recent & Breaking News (NDAQ:OGXI)

OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

Canada NewsWire August 16, 2016

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016

Canada NewsWire August 4, 2016

OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016

Canada NewsWire July 21, 2016

Biotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics

PR Newswire June 27, 2016

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016

Canada NewsWire May 12, 2016

OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016

Canada NewsWire April 28, 2016

These Five Stocks Could Be Ready To Double - Here's Why!

Accesswire April 27, 2016

Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)

Accesswire April 26, 2016

Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016

Accesswire April 26, 2016

OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

Canada NewsWire April 5, 2016

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015

Canada NewsWire March 9, 2016

OncoGenex to Report Fourth Quarter and Year End 2015 Financial Results on March 9, 2016

Canada NewsWire February 24, 2016

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

PR Newswire February 4, 2016

OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

Canada NewsWire January 20, 2016

Market Influences That Drive Equities Forward - New Research on Lionbridge Technologies, Ceres, Tejon Ranch and OncoGenex Pharmaceuticals

Accesswire December 18, 2015

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis

Canada NewsWire December 9, 2015

OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

Canada NewsWire December 1, 2015

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015

Canada NewsWire November 12, 2015

OncoGenex Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference

Canada NewsWire November 5, 2015

OncoGenex to Report Third Quarter 2015 Financial Results on November 12, 2015

Canada NewsWire October 29, 2015